Aberdeen scientists to explore African seas for drug discoveries
Research could lead to new treatments for cancer and MRSA
A team will travel to Ghana next month to search the waters for unique marine organisms that could be used to develop new medicines.
The scientists hope to find previously undiscovered species of corals, sponges and sea squirts. They will examine these organisms for new molecules, bacteria and fungi, which could be used in the creation of new treatments for diseases prevalent in Africa – including tuberculosis and parasitic diseases such as malaria.
Professor Marcel Jaspars, director of the Marine Biodiscovery Centre, said: ‘Drug discovery work in West Africa has historically focused on land, investigating how molecules in plants can be used in the development of new medicines.
‘Our project marks the first time waters off the coast of West Africa have been explored to assess the diversity of marine organisms available in this area, and the potential they could harbour in the treatment of a number of diseases.’
Jaspars said the team would collect samples at low tide around the Gulf of Guinea and Guinea Basin, where they believe they will find new species.
The Aberdeen scientists will work with the University of Ghana during the trip, which marks the beginning of a three-year collaborative project between the two institutions.
The £1.6m Marine Biodiscovery Centre – which brings together chemists and biologists to work on the development of new pharmaceuticals from organisms from the depths of the world’s oceans – opened in June. It is one of only three in Europe dedicated to the exploration of the natural resources from our seas.
The project is funded by the Leverhulme Trust and co-ordinated by the Royal Society.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
The path to commercial allogeneic iPSC therapies
Read moreThe cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Trending Articles
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
The path to commercial allogeneic iPSC therapies
The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Research & Development
The IND advantage: why early derisking is a strategic imperative for complex biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Research & Development
Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies
Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
Research & Development
Lonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation
New GS Ori‑Go vector technology supports titers higher than 11 g/L and reliable bulk pool stability, enabling more predictable material generation and shortened cell line development timelines
Manufacturing
Bruker announces major strides in 4D proteomics performance, further advances In intact and top-down functional proteoform analysis, and innovations in hybrid qual/quant 4D metabolomics
All to enable deeper insights into disease biology. Bruker Also Launches Two Novel Mass Spectrometry Systems for Unique Applications in Energy Industry Research, and in Semiconductor Manufacturing